Pharmena (WAR:PHR) Institutional Ownership : 1.01% (As of Dec. 12, 2024)

View and export this data going back to 2008. Start your Free Trial

What is Pharmena Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Pharmena's institutional ownership is 1.01%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Pharmena's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Pharmena's Float Percentage Of Total Shares Outstanding is 0.00%.

Pharmena Institutional Ownership Historical Data

The historical data trend for Pharmena's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmena Institutional Ownership Chart

Pharmena Historical Data

The historical data trend for Pharmena can be seen below:

	2009-12-31	2010-01-31	2010-02-28	2010-03-31	2010-04-30	2010-05-31	2010-06-30	2010-07-31	2010-08-31	2010-09-30
Institutional Ownership	1.01	1.01	1.01	1.01	1.01	1.01	1.01	1.01	1.01	1.01

Pharmena Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Pharmena Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmena SA (WAR:PHR) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ulica Wolczanska 178, Lodz, POL, 90-530

Website

http://www.pharmena.pl

Pharmena SA produces cosmeceuticals and pharmaceuticals. The company's activity focuses on three areas such as research in the USA and Canada on the application of selected pyridinium salts in medicine in order to develop an anti-atherosclerosis drug on a global scale, Production and sales of innovative patented dermocosmetics and introduction into the market of an innovative dietary supplement for atherosclerosis prophylaxis. Its products include Menavitin, Dermena, Allerco and Thermi.